FY2026 EPS Estimates for InflaRx Lifted by Cantor Fitzgerald

InflaRx N.V. (NASDAQ:IFRX) – Stock analysts at Cantor Fitzgerald raised their FY2026 earnings per share estimates for InflaRx in a report released on Tuesday, November 11th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings per share of ($0.53) for the year, up from their previous forecast of ($0.61). The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Monday, November 10th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million.

IFRX has been the topic of several other research reports. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a report on Tuesday. Guggenheim increased their target price on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright assumed coverage on InflaRx in a research note on Tuesday, September 2nd. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Tuesday. Finally, Wall Street Zen lowered shares of InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

InflaRx Trading Down 7.2%

NASDAQ:IFRX traded down $0.11 on Thursday, hitting $1.36. The company had a trading volume of 2,553,028 shares, compared to its average volume of 1,104,973. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.82. The stock has a market capitalization of $90.97 million, a price-to-earnings ratio of -1.72 and a beta of 1.38. The firm has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.19.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IFRX. Woodline Partners LP purchased a new position in InflaRx in the 1st quarter worth approximately $766,000. 683 Capital Management LLC boosted its holdings in InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock worth $2,678,000 after purchasing an additional 555,000 shares during the period. DAFNA Capital Management LLC acquired a new stake in InflaRx during the first quarter worth about $459,000. Adage Capital Partners GP L.L.C. acquired a new position in InflaRx during the 2nd quarter valued at approximately $262,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after acquiring an additional 91,927 shares during the period. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.